By Fineline Cube China-based Hong Kong WinHealth Pharma Group Ltd has entered into a new partnership with Switzerland-headquartered Ferring Pharmaceuticals Ltd, this time securing co-promotion rights for Ferring’s Pentasa (mesalazine) in mainland China. This collaboration follows previous joint efforts on terlipressin and desmopressin.
Partnership Details
Under the terms of the agreement, WinHealth Pharma will co-promote Pentasa, a well-established treatment for acute ulcerative colitis and maintenance therapy to prevent recurrence, as well as for the symptomatic improvement of active Crohn’s disease. Pentasa has been available in China since 1995, offering sustained-release tablets and suppository dosage forms.
Company Profiles
Ferring Pharmaceuticals, specializing in reproductive medicine, maternal health, gastroenterology, and urology, has a global presence with subsidiaries in nearly 60 countries and products available in 110 locations worldwide. WinHealth Pharma, founded in 2006, is a rare disease specialist with a focus on bringing innovative treatments to patients in need.-Fineline Info & Tech